Ventria Bioscience Inc. Scores Key Victory in Fight Against Infringing Chinese Recombinant Albumin

For immediate release – Junction City, KS  Last week, Ventria Bioscience Inc. obtained an important win in its effort to stop the importation and sale of infringing recombinant albumin made in China by Wuhan Healthgen Biotechnology Corp. On August 18, 2021, the U.S. International Trade Commission (ITC) formally found three U.S. distributors of such products—Aspira […]

Ventria Bioscience’s ExpressTec Delivers the Power to Improve the Health Status of Children in Developing Countries

Junction City, Kansas – November 21, 2019 – A recent publication, Human Milk Proteins: Their Power to Improve the Health Status of Children in Developing Countries, explores the critical health benefits of synthetic human breastmilk proteins for children in developing countries. In poverty-stricken areas, children are more likely to suffer from Environmental Enteric Dysfunction (EED) […]

Biotech Manufacturing Trends from the Bioprocess International 2018 Conference

The Bioprocess International Conference, hosted by the industry-leading publication, Bioprocess International, brings people from across the world in the biotechnology field to share insight, network, and discuss the current and prospects in biologics manufacturing. This years’ conference took place September 4-7 in Boston, Massachusetts and was part of the Boston Biotech week. The conference was split into […]

Digestive Disease Week

Digestive Disease Week(DDW)  is one of the world’s largest conferences, covering a wide array of basic and clinical research topics in the fields of Inflammatory Bowel Diseases (IBD),  cancer,  and liver diseases. At this conference, several companies showcased their GI products, technology, and services for these fields. While there was a lot covered at the conference, […]

The Essential Protein Engineering Summit (PEGS)

The Essential Protein Engineering Summit took place in Boston, MA at the Seaport World Trade Center this year from April 30th – May 4th. PEGS is one of the largest conferences for biotherapeutic protein drug development with over 2,500 industry professionals joining from all over the world. This year’s conference encompassed all of the prominent industry topics including: engineering, […]

Ventria Bioscience CEO interviewed on CNBC

Ventria Bioscience CEO interviewed on CNBC about the importance of protecting scientific creativity and intellectual property. Ventria Bioscience CEO interviewed on CNBC’s Power Lunch and shared his thoughts on the importance of protecting the intellectual property and creativity of scientific innovation that drives progress in global healthcare. Watch this 4-minute video clip on CNBC.

Ventria Bioscience aids global fight against intestinal infections that threaten up to 400 million children a year

Grant from Bill & Melinda Gates Foundation will advance Ventria’s capabilities for production of novel therapeutic proteins Junction City, Kansas – October 23, 2017 – Ventria Bioscience Inc. today announced a $4.2 million grant from the Bill & Melinda Gates Foundation to fund development of efficient biomanufacturing for new therapeutics targeting Enterotoxigenic Escherichia coli (or ETEC), […]

Ventria Bioscience will double biomanufacturing capacity for therapeutic proteins, reagents and cell culture products

Breaks ground to expand scalable, cost-efficient facility in Junction City, Kansas Junction City, Kansas – September 6, 2017 – Ventria Bioscience Inc. today announced an expansion of biomanufacturing and laboratory facilities to roughly double Ventria’s capacity for production of recombinant proteins. The company broke ground today on the expansion of its molecular biology lab, greenhouses, process […]

Ventria Bioscience announces peer-reviewed publication on novel mechanism of action in inflammatory bowel disease

Collaboration with Children’s Hospital Colorado finds Ventria’s recombinant human lactoferrin modulates immune response FORT COLLINS, Colorado – May 17, 2017 – A multi-year collaboration between Ventria Bioscience Inc. and Children’s Hospital Colorado has found a novel mechanism of action that enables Ventria’s recombinant human lactoferrin, VEN120, to reduce inflammation in models of inflammatory bowel disease (IBD). […]

Ventria Wins Economic Development Award

Ventria Bioscience was recognized on February 1 by the Junction City Area Chamber of Commerce with The Eldon L. Hoyle Economic Development Award in acknowledgement of the company’s service, commitment, support and dedication to Junction City and Geary County. Mickey Dean, interim CEO and president of the Chamber, presented the award at the Chamber’s annual […]